Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: Renee who wrote (294)	3/21/1998 1:36:00 AM
From: John Zwiener	Respond to of 1025

Renee, I have been hoping for a 35 million deal for part of the license to POC. If this 100 million deal is true in some form, it seems I have underestimated the POC market. They indicate HP, which would be top noche partner,,,they have been making a good entry into testing instruments. Plus, they bring the computer abilities I feel are essential to a successful POC instrument. I also hear they are honest in their deals, relatively speaking. Up to this point, I have not included POC in any estimates of what it could add as far as value, and this rumor of 100 million seems just to high. On the other hand, I have been caught off guard more than once. I doubt price went up on this kind of rumor. Igen is just catching up to it's minimum worth. Does the nature ad for Architect give any examples of dynamic range and sensitivity? My understanding of these technologies is that chemolum. technology is relatively limited compared to ECL (electrochemolum). It will be an improvement for Abbott, but not as capable as ECL.